Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

  • 1 of 1
Rivaroxaban, marketed by Xarelto

Rivaroxaban is as safe as aspirin and more effective at preventing recurrent venous thromboembolism (VTE) in patients who were in equipoise for continued anticoagulants, a study shows.

Researchers discovered that blood clot rates in patients taking rivaroxaban were significantly lower – 1.5% and 1.2% compared with 4.4% for patients taking aspirin

Source  Annie Eagle / Alamy Stock Photo